This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Pain is experienced by 30% to 50% of ambulatory cancer patients and 75% to 90% of patients with advanced disease. The high prevalence of pain, neuro-oncologic complications of cancer, and neuropathic pain problems make the input of the neurologist an important part of the assessment and management of these patients. Unfortunately, the neurologist receives little specific training in cancer pain assessment or management, and the benefit that could potentially accrue from expert neurologic input often goes unrealized. Gonzales et al from the Memorial Sloan-Kettering Cancer Center (New York, NY) Neurology Pain Service have reported that evaluation resulted in the diagnosis of previously undetected lesions in 64% of consultations, many of which were amenable to primary therapies. There is need, therefore, for a clearly written comprehensive text on cancer pain that could provide the interested clinician with the information necessary to improve the management of these problems.
Cancer Pain, edited by
Chemy NI. Cancer Pain. Arch Neurol. 1994;51(2):113. doi:10.1001/archneur.1994.00540140015002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: